成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Sofosbuvir
1190307-88-0

Sofosbuvir synthesis

5synthesis methods
Sofosbuvir, also known as PSI-7977 and GS7977 (brand names Sovaldi and Virunon), is a drug used for hepatitis C virus (HCV) infection, with a high cure rate. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved for treating chronic Hepatitis C. In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4. Synthetic Description Reference: Wilhelm, Thorsten; Schoene, Olga. Synthesis of sofosbuvir nucleoside phosphoramidate via hydride reduction of ketone. WO 2018134343. (Sandoz AG, Switz) Synthetic Description Reference: Siripragada, Mahender Rao; Kondepati, Venkata Ramana; Dhameliya, Dharmesh; Raval, Prashant; Domadiya, Vipul; Badam, Sreemannarayana; Pirzada, Azim. Process for the preparation of (sp)-sofosbuvir and intermediates thereof. WO 2018025195. (Process for the preparation of (sp)-sofosbuvir and intermediates thereof) Synthetic Description Reference: Reddy, Srinivas Reddy Desi; Velivela, Srinivas Rao. An improved process for the preparation of sofosbuvir. WO 2018015821. (Optimus Drugs (P) Limited, India) Synthetic Description Reference: Gaboardi, Mauro; Pallanza, Giuseppe; Baratella, Marco; Castaldi, Graziano; Castaldi, Marta. Chemoenzymic preparation of sofosbuvir involving a lipase catalyzed regioselective deacetylation. WO 2017144423. (HC-Pharma AG, Switz.) Synthetic Description Reference: Matta, Hari Babu; Sharma, Atul; Shaikh, Shakir Shabbir; Sharma, Kapil; Saini, Anil; Khanna, Mahavir Singh; Prasad, Mohan. Process for the preparation of pure sofosbuvir via coupling reaction as anti-hepatitis C antiviral agent. WO 2017093973. (Sun Pharmaceutical Industries Limited, India) Synthetic Description Reference: Kosik, Kamil; Sagol, Karol; Godzisz, Mateusz. Process for the preparation of sofosbuvir as pharmaceutical agent. EP 3133062. (Zaklady Farmaceutyczne Polpharma SA, Pol.) Synthetic Description Reference: Kosik, Kamil; Sagol, Karol; Godzisz, Mateusz. Process for the preparation of sofosbuvir as pharmaceutical agent. WO 2017029397. (Zaklady Farmaceutyczne Polpharma SA, Pol. 2017) Synthetic Description Reference: Rampalli, Sriram; Upalla, Lav Kumar; Dhkarapu, Veera Venkatarao; Krishna, Dasari Gopal; Chaturvedi, Akshay Kant. An improved process for the preparation of sofosbuvir. WO 2017009746. (Shilpa Medicare Limited, India) Synthetic Description Reference: Schoene, Olga; Wilhelm, Thorsten. Synthesis of phosphoramidates. WO 2016207194. (Sandoz AG, Switz.) Synthetic Description Reference: Kansal, Vinod Kumar; Mistry, Dhirenkumar Natvarial; Achanta, Srinivas; Ariyamuthu, Sundaraselvan; Goswami, Miteshgir Kanchangir; Yazali, Venkata Subbarao. Improved processes for the preparation of sofosbuvir and intermediates thereof via coupling reaction of nucleosides with amino acid. WO 2016196735. (Teva Pharmaceuticals International GmbH, Switz.; Teva Pharmaceuticals USA, Inc. 2016) Synthetic Description Reference: Wilhelm, Thorsten; Schoene, Olga; Spitzenstaetter, Hans-Peter. Selective process for synthesis of nucleoside phosphoramidates via coupling reaction. WO 2016189040. (Sandoz AG, Switz.)
Synthetic Routes
  • ROUTE 1
  • 202112077107496812.jpg

    Reference: Wilhelm, Thorsten; Schoene, Olga. Synthesis of sofosbuvir nucleoside phosphoramidate via hydride reduction of ketone. WO 2018134343. (Sandoz AG, Switz)

  • ROUTE 2
  • 202112070105416607.jpg

    Reference: Siripragada, Mahender Rao; Kondepati, Venkata Ramana; Dhameliya, Dharmesh; Raval, Prashant; Domadiya, Vipul; Badam, Sreemannarayana; Pirzada, Azim. Process for the preparation of (sp)-sofosbuvir and intermediates thereof. WO 2018025195. (Process for the preparation of (sp)-sofosbuvir and intermediates thereof)

  • ROUTE 3
  • 202112076621122608.jpg

    Reference: Reddy, Srinivas Reddy Desi; Velivela, Srinivas Rao. An improved process for the preparation of sofosbuvir. WO 2018015821. (Optimus Drugs (P) Limited, India)

  • ROUTE 4
  • 202112070887298606.jpg

    Reference: Gaboardi, Mauro; Pallanza, Giuseppe; Baratella, Marco; Castaldi, Graziano; Castaldi, Marta. Chemoenzymic preparation of sofosbuvir involving a lipase catalyzed regioselective deacetylation. WO 2017144423. (HC-Pharma AG, Switz.)

  • ROUTE 5
  • 202112074629681387.jpg

    Reference: Matta, Hari Babu; Sharma, Atul; Shaikh, Shakir Shabbir; Sharma, Kapil; Saini, Anil; Khanna, Mahavir Singh; Prasad, Mohan. Process for the preparation of pure sofosbuvir via coupling reaction as anti-hepatitis C antiviral agent. WO 2017093973. (Sun Pharmaceutical Industries Limited, India)

  • ROUTE 6
  • 202112074762390840.jpg

    Reference: Kosik, Kamil; Sagol, Karol; Godzisz, Mateusz. Process for the preparation of sofosbuvir as pharmaceutical agent. EP 3133062. (Zaklady Farmaceutyczne Polpharma SA, Pol.)

  • ROUTE 7
  • 202112079296277283.jpg

    Reference: Kosik, Kamil; Sagol, Karol; Godzisz, Mateusz. Process for the preparation of sofosbuvir as pharmaceutical agent. WO 2017029397. (Zaklady Farmaceutyczne Polpharma SA, Pol. 2017)

  • ROUTE 8
  • 202112072699559215.jpg

    Reference: Rampalli, Sriram; Upalla, Lav Kumar; Dhkarapu, Veera Venkatarao; Krishna, Dasari Gopal; Chaturvedi, Akshay Kant. An improved process for the preparation of sofosbuvir. WO 2017009746. (Shilpa Medicare Limited, India)

  • ROUTE 9
  • 202112071185954496.jpg

    Reference: Schoene, Olga; Wilhelm, Thorsten. Synthesis of phosphoramidates. WO 2016207194. (Sandoz AG, Switz.)

  • ROUTE 10
  • 202112072112726605.jpg

    Reference: Kansal, Vinod Kumar; Mistry, Dhirenkumar Natvarial; Achanta, Srinivas; Ariyamuthu, Sundaraselvan; Goswami, Miteshgir Kanchangir; Yazali, Venkata Subbarao. Improved processes for the preparation of sofosbuvir and intermediates thereof via coupling reaction of nucleosides with amino acid. WO 2016196735. (Teva Pharmaceuticals International GmbH, Switz.; Teva Pharmaceuticals USA, Inc. 2016)

  • ROUTE 11
  • 202112074383449191.jpg

    Reference: Wilhelm, Thorsten; Schoene, Olga; Spitzenstaetter, Hans-Peter. Selective process for synthesis of nucleoside phosphoramidates via coupling reaction. WO 2016189040. (Sandoz AG, Switz.)

202112077107496812.jpg

Reference: Wilhelm, Thorsten; Schoene, Olga. Synthesis of sofosbuvir nucleoside phosphoramidate via hydride reduction of ketone. WO 2018134343. (Sandoz AG, Switz)

863329-66-2 Synthesis
2'-deoxy-2'-fluoro-2'-C-methyluridine

863329-66-2
414 suppliers
$5.00/50mg

-

Yield:1190307-88-0 97.5%

Reaction Conditions:

with pyridine;aluminum (III) chloride in dichloromethane at 20;Reagent/catalyst;Temperature;

Steps:

1-8 Example 1

Add 20.0 g (0.0768 mol) of Compound 1 to the reaction flask, add 40.0 g (0.0882 mol) of Compound 2 and 150 g of dichloromethane, cool to 0 ° C, add aluminum trichloride 3.1 g (0.0232 mol), and add pyridine dropwise 24.3g (0.307mol); then the reaction was performed at 20 ° C, and the reaction was stopped when the content of sofosbuvir was no longer increased by HPLC. At this time, the HPLC data related to compound 1 in the reaction solution:To the reaction solution, 120 g of 10% dilute hydrochloric acid was added to quench the reaction, 300 g of ethyl acetate was extracted, the solvent was recovered under reduced pressure, and 39.68 g of pure Sofibuvir was obtained by purification, with a yield of 97.5%.

References:

CN110950919,2020,A Location in patent:Paragraph 0030-0067

1064684-44-1 Synthesis
PSI 7851

1064684-44-1
19 suppliers
inquiry

Sofosbuvir Related Search: